$SILK
Silk Road Medical Inc Stock $silk

$silk Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000139770220000022 Filed on May 15, 2020

Income Statement

Concept	2020 Q2	2020 Q1	2019 Q1
Revenue	$15.09M	$18.93M	$12.77M
YoY Change	1.11%	48.31%	123.73%
Cost Of Revenue	$5.336M	$5.250M	$3.339M
YoY Change	44.33%	57.23%	72.65%
Gross Profit	$9.758M	$13.68M	$9.427M
YoY Change	-13.12%	45.15%	149.92%
Gross Profit Margin	64.65%	72.27%	73.84%
Selling, General & Admin	$15.76M	$19.69M	$13.87M
YoY Change	11.48%	42.02%	119.43%
% of Gross Profit	161.49%	143.92%	147.09%
Research & Development	$3.393M	$3.131M	$2.707M
YoY Change	8.99%	15.66%	28.9%
% of Gross Profit	34.77%	22.88%	28.72%
Depreciation & Amortization	$190.0K	$184.0K	$174.0K
YoY Change	5.56%	5.75%	205.26%
% of Gross Profit	1.95%	1.34%	1.85%
Operating Expenses	$19.15M	$22.82M	$16.57M
YoY Change	11.03%	37.71%	96.85%
Operating Profit	-$9.393M	-$9.140M	-$7.146M
YoY Change	56.11%	27.9%	53.78%
Interest Expense	$1.203M	$1.202M	$1.352M
YoY Change	-0.33%	-11.09%	36.7%
% of Operating Profit
Other Income/Expense, Net	-$56.00K	-$3.000K	-$15.71M
YoY Change	-98.95%	-99.98%	-7407.91%
Pretax Income	-$10.35M	-$9.940M	-$24.16M
YoY Change	-13.46%	-58.86%	346.58%
Income Tax
% Of Pretax Income
Net Earnings	-$10.35M	-$9.941M	-$24.16M
YoY Change	-13.43%	-58.85%	346.71%
Net Earnings / Revenue	-68.59%	-52.51%	-189.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$316.7K	-$317.2K	-$799.2K
COMMON SHARES
Basic Shares Outstanding	31.47M shares	31.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q2	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$157.9M	$97.60M	$15.50M
YoY Change	33.59%	529.68%
Cash & Equivalents	$73.44M	$27.55M	$15.51M
Short-Term Investments	$84.40M	$70.10M
Other Short-Term Assets	$3.900M	$1.900M	$1.400M
YoY Change	21.88%	35.71%
Inventory	$11.62M	$12.10M	$8.056M
Prepaid Expenses
Receivables	$7.753M	$8.670M	$4.096M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$181.1M	$120.3M	$29.05M
YoY Change	33.28%	314.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.885M	$2.707M	$2.846M
YoY Change	5.18%	-4.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change
Other Assets	$3.233M	$3.444M	$3.982M
YoY Change	-13.16%	-13.51%
Total Long-Term Assets	$6.428M	$6.461M	$9.616M
YoY Change	-5.14%	-32.81%
TOTAL ASSETS
Total Short-Term Assets	$181.1M	$120.3M	$29.05M
Total Long-Term Assets	$6.428M	$6.461M	$9.616M
Total Assets	$187.5M	$126.7M	$38.67M
YoY Change	31.45%	227.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.542M	$3.194M	$3.134M
YoY Change	113.79%	1.91%
Accrued Expenses	$9.142M	$11.13M	$721.0K
YoY Change	10.16%	1443.0%
Deferred Revenue	$335.0K	$174.0K
YoY Change	30.35%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.68M	$14.32M	$10.79M
YoY Change	23.15%	32.68%
LONG-TERM LIABILITIES
Long-Term Debt	$45.07M	$44.97M	$44.60M
YoY Change	0.84%	0.84%
Other Long-Term Liabilities	$3.693M	$3.497M	$4.469M
YoY Change	-9.86%	-21.75%
Total Long-Term Liabilities	$48.76M	$48.47M	$49.07M
YoY Change	-0.06%	-1.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.68M	$14.32M	$10.79M
Total Long-Term Liabilities	$48.76M	$48.47M	$49.07M
Total Liabilities	$60.44M	$62.79M	$91.48M
YoY Change	3.72%	-31.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$211.8M	-$201.5M	-$163.3M
YoY Change	20.88%	23.4%
Common Stock	$34.00K	$31.00K	$1.000K
YoY Change	9.68%	3000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$127.1M	$63.96M	-$158.1M
YoY Change
Total Liabilities & Shareholders Equity	$187.5M	$126.7M	$38.67M
YoY Change	31.45%	227.78%

Cashflow Statement

Concept	2020 Q2	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$10.35M	-$9.941M	-$24.16M
YoY Change	-13.43%	-58.85%	346.71%
Depreciation, Depletion And Amortization	$190.0K	$184.0K	$174.0K
YoY Change	5.56%	5.75%	205.26%
Cash From Operating Activities	-$11.58M	-$11.80M	-$8.620M
YoY Change	23.45%	36.83%	85.38%
INVESTING ACTIVITIES
Capital Expenditures	-$350.0K	$134.0K	$117.0K
YoY Change	288.89%	14.53%	-74.29%
Acquisitions
YoY Change
Other Investing Activities	-$14.46M	$30.00K
YoY Change
Cash From Investing Activities	-$14.80M	-$108.0K	-$117.0K
YoY Change	16344.44%	-7.69%	-74.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$274.0K	$375.0K
YoY Change		-26.93%	32.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	72.27M	274.0K	-$744.0K
YoY Change	-35.59%	-136.83%	-361.97%
NET CHANGE
Cash From Operating Activities	-11.58M	-11.80M	-$8.620M
Cash From Investing Activities	-14.80M	-108.0K	-$117.0K
Cash From Financing Activities	72.27M	274.0K	-$744.0K
Net Change In Cash	45.89M	-11.63M	-$9.481M
YoY Change	-55.33%	22.66%	96.66%
FREE CASH FLOW
Cash From Operating Activities	-$11.58M	-$11.80M	-$8.620M
Capital Expenditures	-$350.0K	$134.0K	$117.0K
Free Cash Flow	-$11.23M	-$11.93M	-$8.737M
YoY Change	20.88%	36.53%	71.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001397702
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3704
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-38847
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	SILK ROAD MEDICAL, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8777622
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1213 Innsbruck Dr.
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunnyvale
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94089
CY2020Q1	dei	City Area Code CityAreaCode	408
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	720-9002
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2020Q1	dei	Trading Symbol TradingSymbol	SILK
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31466720	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27552000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39181000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	70067000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	51508000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8670000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8601000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	12101000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	10322000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1894000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2878000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	120284000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	112490000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	18224000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2707000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2734000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3444000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3644000	USD
CY2020Q1	us-gaap	Assets Assets	126745000	USD
CY2019Q4	us-gaap	Assets Assets	137402000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3194000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1898000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11125000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15034000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14319000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16932000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44972000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44879000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3497000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3700000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	62788000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	65511000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31395637	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31395637	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31255267	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31255267	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	264951000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	263384000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	442000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201467000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-191526000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	63957000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	71891000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	126745000	USD
CY2019Q1	silk	Net Income Loss And Comprehensive Income Loss Net Of Tax Attributable To Parent NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent	-24158000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	52000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	1202000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	1352000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15712000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-9941000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-24158000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	440000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	440000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2020Q1	silk	Net Income Loss And Comprehensive Income Loss Net Of Tax Attributable To Parent NetIncomeLossAndComprehensiveIncomeLossNetOfTaxAttributableToParent	-9501000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.12
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31338310	shares
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	63957000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1200719	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	71891000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	274000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1293000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-9941000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	440000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-134553000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	375000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137402000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18933000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12766000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5250000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3339000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	13683000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	9427000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3131000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2707000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19692000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13866000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	22823000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	16573000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9140000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7146000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	404000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	262000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-24158000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-24158000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-158074000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-9941000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-24158000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	184000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	174000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1293000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	262000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15712000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-79000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11000	USD
CY2019Q1	silk	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	162000	USD
CY2020Q1	silk	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	146000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	83000	USD
CY2019Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	471000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-9000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	92000	USD
CY2019Q1	us-gaap	Inventory Write Down InventoryWriteDown	27000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	60000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-157000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1871000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2339000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-983000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-16000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-55000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	651000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1274000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2287000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3912000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	321000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-203000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1069000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11795000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8620000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	134000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1974000	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	2000000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-117000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1149000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	274000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	375000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	274000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-744000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11629000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9481000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39491000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25300000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27862000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15819000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	1108000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	870000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000	USD
CY2020Q1	silk	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019Q1	silk	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	1204000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3982000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Due to the Coronavirus (“COVID-19”) pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of March 31, 2020. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.</span></div>
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000	USD
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to risks related to the public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company’s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other elective surgical procedures, has significantly decreased as health care organizations globally have prioritized the treatment of patients with COVID-19. For example, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">capacity toward the treatment of COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will significantly impact the Company’s revenue while the pandemic continues.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three months ended March 31, 2020 and 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s accounts receivable are due from a variety of health care organizations in the United States. At March 31, 2020 and December 31, 2019, no customer represented 10% or more of the Company’s accounts receivable. For the three months ended March 31, 2020 and 2019, there were no customers that represented 10% or more of revenue. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div>
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	144140000	USD
CY2020Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	79000	USD
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-9941000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-24158000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31338310	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1200719	shares
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-20.12
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4880866	shares
CY2019Q4	silk	Cash And Cash Equivalents Fair Value Disclosure Maturing After One Year Through Two Years CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears	18224000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28051854	shares
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	96827000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	477000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	35000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	97269000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	97269000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	104093000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	104095000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	104095000	USD
CY2020Q1	silk	Cash And Cash Equivalents Fair Value Disclosure Maturing Within One Year CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear	97269000	USD
CY2019Q4	silk	Cash And Cash Equivalents Fair Value Disclosure Maturing Within One Year CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear	85871000	USD
CY2020Q1	silk	Cash And Cash Equivalents Fair Value Disclosure Maturing After One Year Through Two Years CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears	0	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	97269000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	104095000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P198D
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	15257000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	35000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	29195000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	7000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1539000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1203000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10562000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9119000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	12101000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	10322000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2020Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5642000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9151000	USD
CY2020Q1	silk	Provisions For Sales Returns ProvisionsForSalesReturns	2735000	USD
CY2019Q4	silk	Provisions For Sales Returns ProvisionsForSalesReturns	2419000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	380000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	682000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	769000	USD
CY2020Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	477000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	470000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	174000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	304000	USD
CY2020Q1	silk	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	276000	USD
CY2019Q4	silk	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	431000	USD
CY2020Q1	silk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	181000	USD
CY2019Q4	silk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	241000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	472000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	567000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11125000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15034000	USD
CY2018Q3	silk	Debt Maximum Borrowing Capacity DebtMaximumBorrowingCapacity	15000000	USD
CY2020Q1	silk	Debt Instrument Covenant Maximum Liquidity Amount DebtInstrumentCovenantMaximumLiquidityAmount	3000000	USD
CY2016	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	1000000	USD
CY2017	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	5000000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	217000	USD
CY2018	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	15000000	USD
CY2019	silk	Debt Instrument Covenant Minimum Net Revenue Amount DebtInstrumentCovenantMinimumNetRevenueAmount	30000000	USD
CY2020Q1	silk	Debt Instrument Liquidity Covenant Term DebtInstrumentLiquidityCovenantTerm	P90D
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3347000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4442000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	48255000	USD
CY2020Q1	silk	Long Term Debt Gross Before Accretion Of Closing Fees LongTermDebtGrossBeforeAccretionOfClosingFees	56044000	USD
CY2020Q1	silk	Long Term Debt Accretion Of Closing Fees LongTermDebtAccretionOfClosingFees	1287000	USD
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	57331000	USD
CY2020Q1	silk	Long Term Debt Unpaid Interest LongTermDebtUnpaidInterest	12231000	USD
CY2020Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	128000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	44972000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	217000000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	184000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	193000000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M29D
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3254000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3497000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4285000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	781000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1066000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1096000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1127000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	904000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4974000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	689000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4285000	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	6010000	USD
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	683600	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31395637	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31395637	shares
CY2020Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2020Q1	silk	Common Stock Vote Per Share CommonStockVotePerShare	1	vote
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1554690	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4310790	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	140234000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1250210	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	683600	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.14
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	140370	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.96
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	11379	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	11379	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.87
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2132679	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4842641	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.64
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M3D
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	98677000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2573393	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.81
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M6D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	68839000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4842641	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.64
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M3D
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	98677000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5642000	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.430
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.454
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.427
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0049
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0141
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0254
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1293000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	262000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	17274000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y5M1D
CY2020Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2020Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2020Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2020Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	293000000	USD

Files In Submission

Name	View Source	Status
0001397702-20-000022-index-headers.html	Edgar Link	pending
0001397702-20-000022-index.html	Edgar Link	pending
0001397702-20-000022.txt	Edgar Link	pending
0001397702-20-000022-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
q12020exhibit311.htm	Edgar Link	pending
q12020exhibit312.htm	Edgar Link	pending
q12020exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silk-20200331.htm	Edgar Link	pending
silk-20200331.xsd	Edgar Link	pending
silk-20200331_cal.xml	Edgar Link	unprocessable
silk-20200331_def.xml	Edgar Link	unprocessable
silk-20200331_htm.xml	Edgar Link	completed
silk-20200331_lab.xml	Edgar Link	unprocessable
silk-20200331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILK
Silk Road Medical Inc Stock $silk

2020 Q2 Form 10-Q Financial Statement

#000139770220000022 Filed on May 15, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK Silk Road Medical Inc Stock $silk

2020 Q2 Form 10-Q Financial Statement

#000139770220000022 Filed on May 15, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK
Silk Road Medical Inc Stock $silk